Systemic Sclerosis Diagnosis and Management

Introduction to Systemic Sclerosis

The European League Against Rheumatism (EULAR) recommends using the term "systemic sclerosis" (SSc) over "scleroderma" because SSc encompasses the entire multisystem disease affecting both skin and internal organs, while scleroderma refers specifically to the cutaneous manifestations 1, 2
Systemic sclerosis is characterized by a triad of pathogenic factors: vasculopathy, inflammation/autoimmunity, and fibrosis affecting both skin and internal organs 3

Systemic sclerosis is classified into distinct clinical subsets based on the extent of skin involvement, including limited cutaneous SSc (lcSSc), diffuse cutaneous SSc (dcSSc), and SSc sine scleroderma 4, 5
Nearly all patients (>95%) present with Raynaud phenomenon, and approximately 50% develop digital ulcers 4, 5
Gastrointestinal involvement affects nearly 90% of SSc patients, with the esophagus most commonly affected 4, 6
Interstitial lung disease occurs in 40-75% of patients but is progressive in only 15-18% 4, 5

The modified Rodnan skin score (mRSS) measures skin thickness on a scale of 0-3 at 17 anatomical sites (score range 0-51) 4, 5
Specific autoantibodies help predict disease subtype and organ involvement patterns 5
Comprehensive screening for organ involvement is essential for early detection and management 6, 5

The European League Against Rheumatism (EULAR) recommends targeted therapies for key fibrotic manifestations of SSc 1, 2, 7
Mycophenolate mofetil, nintedanib, rituximab, and tocilizumab are recommended for treating crucial disease manifestations like skin fibrosis and interstitial lung disease 1, 2

Despite recent improvements in survival, SSc remains the rheumatic disease with the highest morbidity and mortality 1, 2
Early detection and treatment of organ involvement significantly impacts prognosis 5

NSAIDs should be used cautiously in systemic sclerosis patients because they may precipitate renal complications, and scleroderma renal crisis requires close monitoring of renal function. 8

Corticosteroids—particularly high‑dose regimens—increase the risk of scleroderma renal crisis; patients receiving steroids need careful blood‑pressure and renal‑function monitoring. 8